Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development

Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients

44% ORR in heavily pre-treated, CDK4/6-experienced patients (median third-line); ORR is similar across kinase and non-kinase PIK3CA mutations

Phase 3 frontline trial in endocrine sensitive patients expected to initiate in early 2027, subject to regulatory feedback

Supply agreement in place with Pfizer to supply atirmociclib for the Phase 3 frontline trial

Relay Therapeutics to host a conference call today, April 27, at 8:30am ET

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced plans to move zovegalisib + atirmociclib, Pfizer's investigational, potential first-in-class CDK4 inhibitor, into Phase 3 development for frontline patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer.